Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)

被引：7
|
作者：
Leonard, R
Miles, D
Reichardt, P
Twelves, C
机构：
[1] S Wales Canc Inst, Swansea, W Glam, Wales
[2] Guys & St Thomas Hosp, London SE1 9RT, England
[3] HELIOS Klinikum, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany
[4] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England
[5] Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England
来源：
SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2004.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：21 / 28
页数：8
相关论文
共 50 条
  • [41] Usefulness of Xeloda, capecitabine for metastatic breast cancer (MBC) In the ambulatory practice
    Rodger, J
    Mickiewicz, E
    Giacomi, N
    Vigo, S
    Tatangelo, M
    Formiels, H
    Coppola, F
    Jovtis, S
    Lastiri, F
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [42] Targeted Therapy of HER2-Negative Breast Cancer
    Schuetz, Florian
    Domschke, Christoph
    Schneeweiss, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (03) : 118 - 121
  • [43] Anthracyclines in the treatment of HER2-negative breast cancer
    Paik, Soonmyung
    Taniyama, Yusuke
    Geyer, Charles E., Jr.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01): : 2 - 4
  • [44] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
  • [45] Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer
    Lv, Huimin
    Yan, Min
    Zhang, Mengwei
    Niu, Limin
    Zeng, Huiai
    Sun, Huihui
    Zhao, Shengnan
    Wang, Jing
    CANCER RESEARCH, 2024, 84 (09)
  • [46] Weekly paclitaxel and capecitabine in HER2-negative metastatic breast cancer (MBC): A multicenter GINECO randomized phase II comparing two paclitaxel-capecitabine schedules
    Lortholary, A.
    Hardy-Bessard, A. C.
    Bachelot, T.
    Dalivoust, P.
    de Rauglaudre, G.
    Alexandre, J.
    Bourgeois, H.
    Jaubert, D.
    Paraiso, D.
    Largillier, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] FULVESTRANT COMBINED WITH CAPECITABINE MAY BE EFFECTIVE AND WELL TOLERATED FOR PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER
    Nakai, Maki
    BREAST, 2015, 24 : S50 - S51
  • [48] Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
    Shah, Ami N.
    Flaum, Lisa
    Helenowski, Irene
    Santa-Maria, Cesar A.
    Jain, Sarika
    Rademaker, Alfred
    Nelson, Valerie
    Tsarwhas, Dean
    Cristofanilli, Massimo
    Gradishar, William
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [49] Phase 3 Trial Comparing Capecitabine in Combination with Sorafenlb or Placebo for Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer (RESILIENCE).
    Baselga, J.
    Schwartzberg, L. S.
    Petrenciuc, O.
    Shan, M.
    Gradishar, W. J.
    CANCER RESEARCH, 2011, 71
  • [50] Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Schwartzberg, Lee S.
    Wang, Grace
    Somer, Bradley G.
    Blakely, L. Johnetta
    Wheeler, Benton M.
    Walker, Mark S.
    Stepanski, Edward J.
    Houts, Arthur C.
    CLINICAL BREAST CANCER, 2014, 14 (01) : 13 - 19
12345